£10,000 ‘golden hellos’ announced to entice nursing post-grads into ‘difficult-to-recruit’ sectors

£10,000 ‘golden hellos’ announced to entice nursing post-grads into ‘difficult-to-recruit’ sectors

May 15 2018 Funding of £10 million will be available to increase recruitment of nurses into...

Scotland announces £6.9m investment in primary care staff training targeted at nursing

Scotland announces £6.9m investment in primary care staff training targeted at nursing

May 9 2018 Funding of £6.9 million will be invested in training primary healthcare staff,...

Nurses offered minimum 6.5% three-year deal on Agenda for Change pay scale

Nurses offered minimum 6.5% three-year deal on Agenda for Change pay scale

March 29 2018 Nurses employed by the NHS could see wages increase by a minimum of 6.5% over the...

NHS England promoting new round of applications for practice pharmacists

NHS England promoting new round of applications for practice pharmacists

January 9 2018 NHS England is reminding health service providers that money is available for...

  • £10,000 ‘golden hellos’ announced to entice nursing post-grads into ‘difficult-to-recruit’ sectors

    £10,000 ‘golden hellos’ announced to entice nursing post-grads into ‘difficult-to-recruit’ sectors

    Tuesday, 15 May 2018 12:13
  • Scotland announces £6.9m investment in primary care staff training targeted at nursing

    Scotland announces £6.9m investment in primary care staff training targeted at nursing

    Wednesday, 09 May 2018 16:15
  • Nurses offered minimum 6.5% three-year deal on Agenda for Change pay scale

    Nurses offered minimum 6.5% three-year deal on Agenda for Change pay scale

    Thursday, 29 March 2018 11:41
  • NHS England promoting new round of applications for practice pharmacists

    NHS England promoting new round of applications for practice pharmacists

    Tuesday, 09 January 2018 11:58

adhdDecember 2 2015

Researchers have urged doctors to be cautious if considering prescribing methylphenidate for children or adolescents with attention deficit hyperactivity disorder (ADHD).

A Cochrane review has concluded that the drug may improve teacher-reported ADHD symptoms, teacher-reported general behaviour, and parent-reported quality of life among children and adolescents diagnosed with ADHD. “However, the low quality of the underpinning evidence means that we cannot be certain of the magnitude of the effects.”

The researchers assessed 38 parallel-group trials and 147 cross-over trials, representing over 12,200 patients, and found methylphenidate led to “modest” improvements in ADHD symptoms as a primary outcome. They also found there were improvements in general behaviour and quality of life. However, in all outcomes, the quality of the evidence was judged to be “very low”.

Data for serious adverse events was only reported in nine out of the 185 trials, meaning that while methylphenidate does not appear to be associated with an increased risk of serious adverse events, the quality of the evidence was again very low.

“It was apparent from assessing the included trials that it would have been possible for people involved in the trials to have been aware of which treatment the children were taking,” says Cochrane. “In addition, the reporting of results was not complete in many of the trials, and for some analyses there was variation among trial results.

“Based upon this information, the researchers urge clinicians to be cautious in prescribing methylphenidate, and to weigh up the benefits and risks more carefully.”

Professor Ole Jakob Storebø, a clinical psychologist from the Psychiatric Research Unit in Region Zealand, Denmark, led the team of 18 researchers carrying out the meta-analysis. “This review highlights the need for long-term, large, better-quality randomized trials so that we can determine the average effect of this drug more reliably,” he said.

Co-author Camilla Groth MD added: “This review shows very limited quality evidence for the effects of methylphenidate on children and adolescents with ADHD. Some might benefit, but we still don’t know which patients will do so. Clinicians prescribing methylphenidate must take account of the poor quality of the evidence, monitor treatment carefully, and weigh up the benefits and adverse effects.”

Links:

Cochrane announcement

Cochrane review summary

Ole Jakob Storebø et al. ‘Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)’. Cochrane Library. Published online November 25 2015.

Management News

June 22 2018 A review into the scheduling of cannabis for medicinal purposes will look for “significant medical and therapeutic benefits” before a decision is made.
June 6 2018 The Royal College of General Practitioners has called for visa regulations to be reviewed to allow more doctors to work as GPs in the NHS. Home Secretary Sajit Javid announced on Sunday...